Wolfgang Miesbach: Targeted Anti-TFPI Therapy with Marstacimab Supports Joint Stability in Hemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”Michael Sigl-Kraetzig and colleagues presented at GTH 2026 in Bonn the first European real-world experience with Marstacimab in a patient with haemophilia A and advanced haemophilic arthropathy.
The poster describes a switch from intravenous factor prophylaxis to subcutaneous anti-TFPI prophylaxis (Marstacimab) in a patient with poor prior adherence, resulting in a lower treatment burden and markedly improved adherence.
Joint status was monitored clinically and by standardised ultrasound (HEAD-US), enabling structured assessment of arthropathy progression.
Following a post-traumatic bleed, treatment was escalated to a doubled Marstacimab dose, with ongoing excellent adherence and no thromboembolic events reported so far.
This case highlights how targeted anti-TFPI therapy, combined with standardised imaging and individualised dose adjustment, may support adherence and help stabilise joint outcomes in haemophilia care.”
Stay updated with Hemostasis Today.
-
Apr 16, 2026, 14:05Saleh Shamse Basha: When Platelet Counts Mislead, The PLT-F Becomes Critical
-
Apr 16, 2026, 13:44Maha Othman: Celebrating National Medical Laboratory Week in Canada
-
Apr 16, 2026, 13:42Megan Adediran: How Much of What You Know About Hemophilia Is True?
-
Apr 16, 2026, 13:35Priya Singh: How to Write the Discussion of a Research Paper
-
Apr 16, 2026, 13:14Veronica Sanchez: Blood Pressure Categories for Individuals Who Are Pregnant
-
Apr 16, 2026, 13:07Abdul Mannan: Acute Anaphylactic Reaction During Blood Transfusion
-
Apr 16, 2026, 09:41Wolfgang Miesbach: Adeno-Associated Virus Neutralizing Antibodies and Their Clinical Impact on Gene Therapy
-
Apr 16, 2026, 09:33Jeyaraj Pandian: Low-Cost Stroke Rehabilitation Technologies at MENA-VINM 2026
-
Apr 16, 2026, 09:21Aurore Ughetto: The Hemocompatibility Burden of Micro-Axial Flow Pump Support